Literature DB >> 16493158

Pulmonary arterial hypertension.

Lewis J Rubin1.   

Abstract

Pulmonary arterial hypertension (PAH) is a term used to classify a variety of conditions that have in common an injury to the pulmonary vasculature that produces elevations in pulmonary arterial pressure. There have been considerable advances in our understanding of the pathogenesis and treatment of PAH over the past decade. The article reviews the classification of diseases associated with PAH, the current understanding of its pathogenesis, and the contemporary approach to therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493158     DOI: 10.1513/pats.200510-112JH

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  28 in total

Review 1.  Novel approaches to pulmonary arterial hypertension drug discovery.

Authors:  Yon K Sung; Ke Yuan; Vinicio A de Jesus Perez
Journal:  Expert Opin Drug Discov       Date:  2016-02-27       Impact factor: 6.098

2.  Effect of chronic sodium nitrite therapy on monocrotaline-induced pulmonary hypertension.

Authors:  Edward A Pankey; Adeleke M Badejo; David B Casey; George F Lasker; Russel A Riehl; Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Nitric Oxide       Date:  2012-03-14       Impact factor: 4.427

3.  miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia.

Authors:  Deming Gou; Ramaswamy Ramchandran; Xiao Peng; Lijun Yao; Kang Kang; Joy Sarkar; Zhixin Wang; Guofei Zhou; Goufei Zhou; J Usha Raj
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-08-10       Impact factor: 5.464

Review 4.  Molecular pathogenesis and current pathology of pulmonary hypertension.

Authors:  Vinicio A de Jesus Perez
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

5.  MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells.

Authors:  Kang Kang; Xiao Peng; Xiaoying Zhang; Yuna Wang; Lishu Zhang; Li Gao; Tingting Weng; Honghao Zhang; Ramaswamy Ramchandran; J Usha Raj; Deming Gou; Lin Liu
Journal:  J Biol Chem       Date:  2013-07-12       Impact factor: 5.157

6.  Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension.

Authors:  C Agard; M Rolli-Derkinderen; E Dumas-de-La-Roque; M Rio; C Sagan; J P Savineau; G Loirand; P Pacaud
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

7.  Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the cAMP-PKA pathway.

Authors:  Koichiro Kamio; Xiangde Liu; Hisatoshi Sugiura; Shinsaku Togo; Tetsu Kobayashi; Shinsaku Kawasaki; Xingqi Wang; Lijun Mao; Youngsoo Ahn; Cory Hogaboam; Myron L Toews; Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-15       Impact factor: 6.914

8.  Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats.

Authors:  Mariko Harada-Shiba; Itaru Takamisawa; Kanjiro Miyata; Takehiko Ishii; Nobuhiro Nishiyama; Keiji Itaka; Kenji Kangawa; Fumiki Yoshihara; Yujiro Asada; Kinta Hatakeyama; Noriya Nagaya; Kazunori Kataoka
Journal:  Mol Ther       Date:  2009-03-31       Impact factor: 11.454

9.  Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.

Authors:  Shelley Shapiro; David M Pollock; Hunter Gillies; Noreen Henig; Martine Allard; Christiana Blair; Crystal Anglen; Donald E Kohan
Journal:  Am J Cardiol       Date:  2012-08-02       Impact factor: 2.778

Review 10.  Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension.

Authors:  Robert Tulloh
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.